Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- Ogen 2.5 (estropipate)
- pexidartinib
Interactions between your drugs
estropipate pexidartinib
Applies to: Ogen 2.5 (estropipate), pexidartinib
Pexidartinib may reduce the blood levels and effects of estropipate. If you are using low-dose oral contraceptives, you may have an increased risk of breakthrough bleeding and unintended pregnancy. You should discuss the use of alternative or additional methods of birth control with your healthcare provider. If you take hormone replacement for menopause, notify your doctor if your medication is no longer controlling your symptoms or you experience abnormal bleeding. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
pexidartinib food
Applies to: pexidartinib
You may experience reduced absorption of pexidartinib in the presence of food. Pexidartinib should be taken on an empty stomach at least 1 hour before or 2 hours after food. This will make it easier for your body to absorb the medication. Also, while taking pexidartinib, you should avoid grapefruits and grapefruit juice. Grapefruit and grapefruit juice can raise the levels of pexidartinib in your body and lead to potentially dangerous adverse effects. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
estropipate food
Applies to: Ogen 2.5 (estropipate)
Information for this minor interaction is available on the professional version.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Evenity
Evenity (romosozumab) injection is used to treat osteoporosis in postmenopausal women to reduce the ...
Prolia
Prolia (denosumab) is an injection that is administered subcutaneously (under the skin) once every ...
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Fosamax
Fosamax (alendronate) is used to treat or prevent postmenopausal osteoporosis and steroid-induced ...
Premarin
Premarin is used to treat symptoms of menopause such as hot flashes, and vaginal dryness. Learn ...
Reclast
Reclast (zoledronic acid) is used to treat osteoporosis in women after menopause and also to treat ...
Estrace
Estrace (estradiol) is used to treat symptoms of menopause such as hot flashes and vaginal dryness ...
Zometa
Zometa is used to treat high blood levels of calcium caused by cancer and multiple myeloma. Learn ...
Xgeva
Xgeva prevents bone fractures and other skeletal conditions in people with multiple myeloma, and is ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.